ASCO QOPI
Quality Oncology Practice Initiative

QOPI® 2020 REPORTING TRACKS

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
x	x	x	x		x	Core	1	Pathology report confirming malignancy*	
x	x	x	x		x	Core	2	Staging documented within one month of first office visit*	NQF Endorsed #0386 (adapted)
	x	x		x	x	Core	3	Pain assessed by second office visit	NQF Endorsed #0383/#0384 (adapted)
x	x	x		x		Core	4a	Pain intensity quantified by second office visit	NQF Endorsed #0384 (adapted)
	x	x		x		Core	5	Plan of care for moderate/severe pain documented	NQF Endorsed #0383/#0384 (adapted)
	x	x	x	x		Core	6	Pain addressed appropriately (defect-free measure 3, 4a, 5)*	NQF Endorsed #0383 (adapted)
	x	x	x			Core	6a	Pain assessed on either of the two most recent office visits*	NQF Endorsed #0383/#0384 (adapted)
	x	x				Core	6b	Pain intensity quantified on either of the two most recent office visits	NQF Endorsed #0383/#0384 (adapted)
	x	x				Core	6c	Plan of care for moderate/severe pain documented on either of the two most recent office visits	NQF Endorsed #0383/#0384 (adapted)

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries

QOPI® 2020 REPORTING TRACKS

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
	x	x				Core	6d	Pain addressed appropriately on either of the two most recent office visits (defect-free measure, 6a, 6b, 6c)	NQF Endorsed #0383/#0384 (adapted)
	x	x				Core	6e	Pain addressed appropriately by second office visit and during most recent office visits (defect-free measure 6 and 6d)	NQF Endorsed #0383/#0384 (adapted)
	x	x	x	x	x	Core	9	Documented plan for chemotherapy, including doses, route, and time intervals*	
	x	x	x	x		Core	10	Chemotherapy intent (curative vs. non-curative) documented before or within two weeks after administration*	
	x	x	x	x		Core	11	Chemotherapy intent discussion with patient documented*	
					x	Core	12	Number of chemotherapy cycles documented (used in LMIC Track only)	
	x	x		x		Core	13	Chemotherapy planning completed appropriately (defect-free measure, 9, 10, 12)	
	x	x				Core	13aa	Performance status documented prior to initiating chemotherapy regimen	
	x	x				Core	13a1	Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented. (Lower Score - Better) (Defect-free measure 13a1a, 13a1b)	
	x	x				Core	13a1a	Chemotherapy administered to patients with metastatic solid tumor with performance status of 3 or 4 (Lower Score - Better)	
	x	x				Core	13a1b	Chemotherapy administered to patients with metastatic solid tumor with performance status undocumented (Lower Score - Better)	
	x	x				Core	13oc4	Documented plan for oral chemotherapy (defect-free Measure, 13oc4a - 13oc4d) (Test Measure)	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
	x	x	x			Core	13oc4a	Documented plan for oral chemotherapy: Dose*	
	x	x	x			Core	13oc4b	Documented plan for oral chemotherapy: Administration schedule (start day, days of treatment/rest and planned duration)*	
	x	x				Core	13oc4c	Documented plan for oral chemotherapy: provided to patient/caregiver prior to start of therapy and practitioner(s) providing continuing care (PCP) within 3 months of starting therapy (Test Measure)	
	x	x				Core	13oc4d	Documented plan for oral chemotherapy: Indications	
	x	x				Core	13oc5	Oral chemotherapy education provided prior to the start of therapy (defect-free Measure, 13oc5a - 13oc5c)	
	x	x				Core	13oc5a	Oral chemotherapy education provided prior to the start of therapy: Missed doses	
	x	x				Core	13oc5b	Oral chemotherapy education provided prior to the start of therapy: Toxicities	
	x	x				Core	13oc5c	Oral chemotherapy education provided prior to the start of therapy: Clinic contact instructions	
	x	x				Core	13oc6	Oral chemotherapy monitored on visit/contact following start of therapy (defect-free Measure 13oc6a - 13oc6b)	
	x	x				Core	13oc6a	Oral chemotherapy monitored on visit/contact following start of therapy: Medication adherence assessed	
	x	x				Core	13oc6b	Oral chemotherapy monitored on visit/contact following start of therapy: Medication adherence addressed	
	x	x				Core	14	Signed patient consent for chemotherapy	
	x	x				Core	15	Patient consent documented in practitioner note	
	x	x	x			Core	16	Patient consent for chemotherapy (combined measure, 14, or 15)*	
	x	x		x		Core	17	Chemotherapy treatment summary completed within 3 months of chemotherapy treatment end	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries

QOPI® 2020 REPORTING TRACKS

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
	x	x		x		Core	18	Chemotherapy treatment summary provided to patient within 3 months of chemotherapy end	
	x	x		x		Core	19	Chemotherapy treatment summary provided or communicated to practitioner(s) within 3 months of chemotherapy end	
x	x	x	x	x		Core	21aa	Smoking status/tobacco use documented in past year*	NQF Endorsed #0028 (adapted)
x	x	x		x		Core	22aa	Smoking/tobacco use cessation counseling recommended to smokers/tobacco users in past year	NQF Endorsed #0028 (adapted)
	x	x		x		Core	22bb	Tobacco cessation counseling administered or patient referred in past year	NQF Endorsed #0028 (adapted)
	x	x		x		Core	23aa	Smoking/tobacco use cessation administered appropriately in the past year (defect-free measure 21aa, 22aa, 22bb)	NQF Endorsed #0028 (adapted)
	x	x	x	x		Core	24	Patient emotional well-being assessed by the second office visit*	
	x	x	x	x		Core	25	Action taken to address problems with emotional well-being by the second office visit*	
	x	x		x		Core	25a	Documentation of patient's advance directives by the third office visit	
x	x	x	x			Core	25b	Height, Weight, and BSA documented prior to chemotherapy*	
			x			Symptom/ Toxicity	30	Appropriate Antiemetic Therapy for High- and Moderate-Emetic-Risk Antineoplastic Agents*	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
			x			Symptom/ Toxicity	31	Antiemetic Therapy for Low- and Minimal-Emetic-Risk Antineoplastic Agents – Avoidance of Overuse (Lower Score – Better)*	
	x	x	x	x		Symptom/ Toxicity	33	Infertility risks discussed prior to chemotherapy with patients of reproductive age*	
	x	x		x		Symptom/ Toxicity	34	Fertility preservation options discussed or referral to specialist	
						EOL	35	Pain assessed on either of the last two visits before death	NQF Endorsed #0383/#0384 (adapted)
						EOL	36a	Pain intensity quantified on either of the last two visits before death	NQF Endorsed #0383/#0384 (adapted)
						EOL	37	Plan of care for moderate/severe pain documented on either of the last two visits before death	NQF Endorsed #0383/#0384 (adapted)
						EOL	38	Pain addressed appropriately (defect-free measure 35, 36a, 37)	NQF Endorsed #0383/#0384 (adapted)
						EOL	39	Dyspnea assessed on either of the last two visits before death	
						EOL	40	Dyspnea addressed on either of the last two visits before death	
						EOL	41	Dyspnea addressed appropriately (defect-free measure 39, 40)	
						EOL	42	Hospice enrollment	NQF Endorsed #0215 (adapted)

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
						EOL	43a	Palliative care referral/services	NQF Endorsed #0215 (adapted)
						EOL	44	Hospice enrollment within 3 days of death (Lower Score – Better)	NQF Endorsed #0216 (adapted)
						EOL	45	Hospice enrollment within 7 days of death (Lower Score – Better)	NQF Endorsed #0216 (adapted)
						EOL	46	For patients not referred, hospice or palliative care discussed within the last 2 months of life	NQF Endorsed #0215 (adapted)
						EOL	47a	Hospice enrollment, or documented discussion (Combined measure 42 or 46)	
						EOL	47b	Palliative care referral/services, or documented discussion (Combined measure 43 or 46)	
						EOL	48	Chemotherapy administered within the last 2 weeks of life (Lower Score - Better)	NQF Endorsed #0210
						EOL	49ed	Percentage of patients who died from cancer with more than one emergency department visit in the last 30 days of life (Lower Score – Better)	NQF Endorsed #0211
						EOL	49icu	Percentage of patients who died from cancer admitted to the ICU in the last 30 days of life (Lower Score – Better)	NQF Endorsed #0213
						Breast	52	Combination chemotherapy recommended within 4 months of diagnosis for women under 70 with AJCC stage IA (T1c) and IB-III ER/PR negative breast cancer	NQF Endorsed #0559 (adapted)

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
						Breast	52a	Complete staging for women with invasive breast cancer (Cancer stage, HER2, and ER/PR status)	
			x			Breast	53	Combination chemotherapy received within 4 months of diagnosis by women under 70 with AJCC stage IA (T1c) and IB - III ER/PR negative breast cancer*	NQF Endorsed #0559 (adapted)
			x			Breast	54	Test for Her-2/neu overexpression or gene amplification*	NQF Endorsed #1878 (adapted)
						Breast	55	Trastuzumab recommended for patients with AJCC stage I (T1c) to III Her-2/neu positive breast cancer	NQF Endorsed #1858 (adapted)
						Breast	57a	Appropriate treatment for patients with stage I (T1c) – III HER-2 positive breast cancer	
						Breast	58	Tamoxifen or AI recommended within 1 year of diagnosis for patients with AJCC stage IA (T1c) and IB - III ER or PR positive breast cancer	NQF Endorsed #0220/#0387 (adapted)
			x			Breast	59	Tamoxifen or AI received within 1 year of diagnosis by patients with AJCC stage IA(T1c) and IB - III ER or PR positive breast cancer*	NQF Endorsed #0220/#0387 (adapted)
						Breast	61	IV bisphosphonates or denosumab administered for breast cancer bone metastases	
						Breast	62a1	PET, CT, or radionuclide bone scan ordered by practice within 60 days after diagnosis to stage I, IIA, or IIB breast cancer (Lower Score - Better)	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
						Breast	62b1	PET, CT, or radionuclide bone scan ordered by practice between day 61 and day 365 after diagnosis of breast cancer in patients who received treatment with curative intent (Lower Score - Better) (Top 5 Measure)	
						Breast	62c1	Serum tumor marker surveillance ordered by practice between 30 days and 365 days after diagnosis of breast cancer in patients who received treatment with curative intent for breast cancer (Lower Score - Better) (Top 5 Measure)	
						Breast	62d	GCSF administered to patients who received chemotherapy for metastatic breast cancer (Lower Score - Better)	
						Colorectal	63a	Presence or absence of cancer in first-degree blood relatives documented	
			x			Colorectal	66	CEA within 4 months of curative resection for colorectal cancer*	
						Colorectal	67	Adjuvant chemotherapy recommended within 4 months of diagnosis for patients with AJCC stage III colon cancer	NQF Endorsed #0223/#0385 (adapted)
			x			Colorectal	68	Adjuvant chemotherapy received within 2 months of diagnosis by patients with AJCC stage III colon cancer*	NQF Endorsed #0223/#0385 (adapted)
						Colorectal	70	12 or more lymph nodes examined for resected colon cancer	NQF Endorsed #0225 (adapted)
			x			Colorectal	73	Colonoscopy before or within 6 months of curative colorectal resection or completion of primary adjuvant chemotherapy*	NQF Endorsed #1859 (adapted)

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
			x			Colorectal	74	RAS (KRAS and NRAS) testing for patients with metastatic colorectal cancer who received anti-EGFR MoAb therapy*	NQF Endorsed #1860 (adapted)
						Colorectal	75	Anti-EGFR MoAb therapy received by patients with KRAS and NRAS mutation (Lower Score- Better)	NQF Endorsed #1860 (adapted)
						Colorectal	75b	GCSF administered to patients who received chemotherapy for metastatic colon cancer (Lower Score - Better)	
						Colorectal	76	Avoid Surveillance PET and PET-CT Scanning in Patients with Asymptomatic Colon Cancer Treated for Curative Intent	
						Colorectal	77msi	MSI Status in Colorectal Cancer	
						Colorectal	78	Transrectal ultrasound or pelvic MRI for non-metastatic rectal cancer patients	
						NHL	77	Obinutuzumab, ofatumumab, or rituximab administered when CD- antigen expression is negative or undocumented (Lower Score – Better)	
						NHL	78a	Hepatitis B virus infection test (HBsAg) and Hepatitis B core antibody (Anti-HBc) test within 3 months prior to initiation of Obinutuzumab, ofatumumab, or rituximab for patients with NHL	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
						NHL	80n	Percentage of patients with PET or PET-CT ordered by practice between 3 and 12 months after completion of treatment with curative intent for diffuse large B cell lymphoma (Lower Score – Better)	
x						NSCLC	81	Adjuvant cisplatin-based chemotherapy received within 60 days after curative resection by patients with AJCC stage II or IIIA NSCLC	
x						NSCLC	82	Adjuvant chemotherapy recommended for patients with AJCC stage IA NSCLC (Lower Score - Better)	
x						NSCLC	83	Adjuvant radiation therapy recommended for patients with AJCC stage IB or II NSCLC (Lower Score - Better)	
x			x			NSCLC	84	Performance status documented for patients with initial AJCC stage IV or distant metastatic NSCLC*	
x			x			NSCLC	88	Patients with Stage IV NSCLC with adenocarcinoma histology with an activating EGFR mutation or ALK gene rearrangement who received first-line EGFR tyrosine kinase inhibitor or other targeted therapy*	
x						NSCLC	89	Patients with Stage IV NSCLC with EGFR mutation status unknown or without an activating EGFR mutation or ALK gene rearrangement who received first-line EGFR tyrosine kinase inhibitor or ALK inhibitor (Lower Score - Better)	
						NSCLC	89a	GCSF administered to patients who received chemotherapy for metastatic NSCLC cancer (Lower Score - Better)	
x						NSCLC	90	PET or PET-CT ordered by the practice between 0 and 12 months after treatment with curative intent for patients with Stage I or Stage II NSCLC (Lower Score – Better)	
x						NSCLC	91	Molecular Testing for Patients with Stage IV NSCLC with Adenocarcinoma Histology	
x						NSCLC	92	Molecular Testing Turnaround Time for Patients with Stage IV NSCLC with Adenocarcinoma Histology (Test Measure)	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries

QOPI® 2020 REPORTING TRACKS

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
x						NSCLC	93	Concurrent Chemoradiation for Patients with a Diagnosis of Stage IIIB NSCLC (Test Measure)	
						GYNONC	90g	Operative report with documentation of residual disease within 48 hours of cytoreduction for women with invasive ovarian, fallopian tube, or peritoneal cancer	
						GYNONC	91g	Complete staging for women with invasive stage I-IIIB ovarian, fallopian tube, or peritoneal cancer who have undergone cytoreduction	
			x			GYNONC	94	Platin or taxane administered within 42 days following cytoreduction to women with invasive stage I (grade 3), IC-IV ovarian, fallopian tube, or peritoneal cancer*	NQF Endorsed #0218
						GYNONC	95	VTE prophylaxis administered within 24 hours of cytoreduction to women with invasive ovarian, fallopian tube, or peritoneal cancer	NQF Endorsed #0527
						GYNONC	96	Order for prophylactic parenteral antibiotic administration within 1-2 hours before cytoreduction for women with invasive ovarian, fallopian tube, or peritoneal cancer	NQF Endorsed #0529
						GYNONC	97	Order for prophylactic parenteral antibiotic discontinuation within 24 hours after cytoreduction for women with invasive ovarian, fallopian tube, or peritoneal cancer	
				x		Palliative Care	98	Pain quantified using a standardized instrument at every clinical encounter in the past 3 months for patients with advanced/metastatic lung, pancreatic and colorectal cancer	
				x		Palliative Care	99	Plan of care for pain when moderate/severe pain present in the past 3 months for patients with advanced/metastatic lung, pancreatic and colorectal cancer	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
				x		Palliative Care	100	Constipation, fatigue, and nausea assessed at the clinic visit following a new prescription or increasing opioid regimen for patients with advanced/metastatic lung, pancreatic and colorectal cancer	
				x		Palliative Care	101	Dyspnea assessed on every clinic visit in the past 3 months for patients with advanced/metastatic lung, pancreatic and colorectal cancer	
				x		Palliative Care	102	Dyspnea addressed, if present, in the past 3 months for patients with advanced/metastatic lung, pancreatic and colorectal cancer	
				x		Palliative Care	103	Nausea and vomiting assessed on every clinic visit in the past 3 months for patients with advanced/metastatic lung, pancreatic and colorectal cancer	
				x		Palliative Care	104	Nausea and vomiting addressed, when present, in the past 3 months for patients with advanced/metastatic lung, pancreatic and colorectal cancer	
				x		Palliative Care	106	Emotional well-being assessed within first 2 visits after diagnosis with advanced/metastatic lung, pancreatic and colorectal cancer	
				x		Palliative Care	109	Advance directive documentation within first 3 visits after diagnosis with advanced/metastatic lung, pancreatic and colorectal cancer	
						Prostate	111	PET, CT, or radionuclide bone scan ordered by practice within 2 months after diagnosis to stage prostate cancer with low risk of metastases (Lower Score – Better) (Test Measure)	
						Prostate	115	Percentage of patients with a diagnosis of prostate cancer receiving abiraterone for whom the medication is appropriately administered and monitored	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries

IASLC[1]	New to QOPI	Fellowship	QOPI Certification	Patient-Centered	LMIC[2]	Module	Measure #	MEASURES	NQF Endorsed Measure (adapted)
						Prostate	116a	Docetaxel, abiraterone, enzalutamide or apalutamide ordered for patients with metastatic, hormone-sensitive prostate cancer undergoing androgen deprivation therapy (ADT) (Test Measure)	
						Prostate	117	Percentage of patients, regardless of age, with a diagnosis of prostate cancer at high or very high risk of recurrence receiving external beam radiotherapy to the prostate who were prescribed adjuvant hormonal therapy (GnRH [gonadotropin-releasing hormone] agonist or antagonist)	NQF 0390
x						SCLC	118	Prophylactic Cranial Irradiation for Patients with Limited Stage (LS) Small Cell Lung Cancer (SCLC)	
x						SCLC	119	Overtreatment of SCLC Patients with Platinum-Based Chemotherapy	
x						SCLC	120	Early Thoracic Radiotherapy (TRT) for Patients with a Diagnosis of Limited Stage SCLC	
						Melanoma	121	Sentinel Lymph Node (SLN) Biopsies for Patients with AJCC T1b-T4 Melanoma	
						Melanoma	122	BRAF Molecular Screening During Workup for Advanced Melanoma	
						Melanoma	123	Screening for Brain Metastases at Initial Diagnosis of Advanced Melanoma	

*QOPI® Certification Measure
1) International Association for the Study of Lung Cancer
2) Low and Middle Income Countries